Biocon Share Price Target Tomorrow From 2025 To 2030- Current Graph, Financials

Biocon is a leading biotechnology company from India, known for making life-saving medicines that are both high in quality and affordable. The company focuses on areas like diabetes, cancer, and immune diseases, offering treatments through its biosimilars and generic drugs. Many people trust Biocon for its strong commitment to healthcare and innovation. Biocon Share Price on NSE as of 31 May 2025 is 334.45 INR. This article will provide more details on Biocon Share Price Target 2025, 2026 to 2030.

Biocon Ltd: Company Info

• CEO: Siddharth Mittal (1 Dec 2019–)
• Founded: 1978
• Founder: Kiran Mazumdar-Shaw
• Headquarters: Bengaluru
• Number of employees: 16,315 (2024)
• Revenue: 11,550 crores INR (US$1.4 billion, 2023)
• Subsidiaries: Biocon Biologics Limited, Biocon Pharma Limited

Biocon Share Price Chart

Biocon Share: Market Overview

• Open: 335.05
• High: 337.60
• Low: 331.40
• Mkt cap: 40.21KCr
• P/E ratio: 39.53
• Div yield: 0.15%
• 52-wk high: 404.70
• 52-wk low: 269.55

Biocon Share Price Target Tomorrow From 2025 To 2030

Here are the estimated share prices of Biocon for the upcoming years, based solely on market valuation, enterprise trends and professional predictions.

• 2025 – ₹410
• 2026 – ₹450
• 2027 – ₹490
• 2028 – ₹530
• 2029 – ₹570
• 2030 – ₹610

Biocon Share Price Target 2025

Biocon share price target 2025 Expected target could be between ₹400 to ₹410. Here are seven key factors influencing the growth of Biocon Limited’s share price target for 2025:

1. Strong Performance in Biosimilars Segment
   Biocon Biologics, the company’s biosimilars division, delivered a robust 15% year-on-year revenue growth in FY25, reaching ₹9,017 crore. This segment contributed 58% to the company’s overall revenue, driven by significant market share gains in the U.S. and other regulated markets.

2. Expansion in Generics and Peptides Portfolio
   The Generics business achieved a healthy 46% year-on-year growth in Q4 FY25, concluding the fiscal year with an overall 8% growth. The launch of generic Liraglutide and developments in GLP-1 peptides, such as Semaglutide and Tirzepatide, are expected to be key growth drivers in the near and long term.

3. Regulatory Approvals Enhancing Market Access
   Biocon received U.S. FDA approval for its biologics unit in Bengaluru, which obtained a “Voluntary Action Indicated” (VAI) status. This approval clears the path for Biocon to continue its operations without disruptions and enhances its prospects in the lucrative U.S. market.

4. Strategic Collaborations and Partnerships
   Biocon is seeking partnerships, such as in China, to conduct clinical trials for generic versions of Novo Nordisk’s diabetes drug Ozempic and weight loss treatment Wegovy. These collaborations aim to expand Biocon’s global footprint and tap into high-demand markets.

5. Positive Analyst Outlook and Upgraded Ratings
   Brokerage firms like HSBC and Motilal Oswal have upgraded Biocon to a ‘Buy’ rating, setting target prices of ₹430 per share. The optimism stems from expected operational turnaround, key biosimilar launches, and recovery in generics sales.

6. Capital Expenditure for Capacity Expansion
   Biocon plans to invest $150 million in capital expenditure over the next two years, with $100 million allocated to its biologics division and the remaining amount supporting its generics business. This strategic investment aims to bolster Biocon’s capabilities and growth in these key sectors.

7. Favorable Industry Trends and Government Initiatives
   India’s biotechnology sector is projected to reach a valuation of $150 billion by 2025 and surpass $300 billion by 2030. Government initiatives like the Bio-RIDE scheme aim to advance biotechnology, biomanufacturing, and biofoundries, providing a conducive environment for companies like Biocon to thrive.

Biocon Share Price Target 2030

Biocon share price target 2030 Expected target could be between ₹600 to ₹610. Here are seven key risks and challenges that could impact Biocon Limited’s share price target by 2030:

1. Regulatory Delays and Compliance Issues
   Biocon has faced delays in obtaining approvals for several biosimilar products in the U.S. market, such as bAspart and bBevacizumab. These setbacks, often due to regulatory hurdles and facility-related concerns, can postpone product launches and affect revenue projections.

2. Intensifying Market Competition
   The biosimilars and generics sectors are becoming increasingly competitive, with numerous players entering the market. This heightened competition can lead to pricing pressures and reduced market share, impacting Biocon’s profitability.

3. Dependence on Key Markets
   A significant portion of Biocon’s revenue is derived from the U.S. and European markets. Any adverse changes in regulatory policies, market dynamics, or economic conditions in these regions can pose risks to the company’s financial performance.

4. Challenges in Product Pipeline Execution
   While Biocon has a robust pipeline of biosimilars and novel biologics, bringing these products to market involves substantial research and development efforts, clinical trials, and regulatory approvals. Delays or failures in these processes can hinder growth prospects.

5. Currency Fluctuations
   Operating in multiple international markets exposes Biocon to foreign exchange risks. Volatility in currency exchange rates can impact the company’s earnings and profitability.

6. Intellectual Property and Patent Challenges
   Navigating the complex landscape of patents and intellectual property rights is crucial for Biocon. Legal disputes or challenges related to patents can delay product launches and increase operational costs.

7. Operational Risks and Supply Chain Disruptions
   Biocon’s operations are susceptible to risks such as manufacturing disruptions, quality control issues, and supply chain interruptions. Such operational challenges can affect product availability and financial performance.

Shareholding Pattern For Biocon Share

Biocon Financials